AUSTRALIAN CLINICAL LABS LIMITED (ACL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ACL - AUSTRALIAN CLINICAL LABS LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$4.24

21 Oct
2021

0.010

OPEN

$4.26

0.24%

HIGH

$4.33

996,769

LOW

$4.20

TARGET
$4.50 6.1% upside
OTHER COMPANIES IN THE SAME SECTOR
EBO . SLA . CAJ . GXL . HSO . MPL . MVF . NHF . HLS . RHC . SHL . VRT . M7T . HLA . PSQ . SIL . PKS . ONT . DOC . NVL . AHX . ALC .
FNARENA'S MARKET CONSENSUS FORECASTS
ACL: 1
Title FY20
Actual
FY21
Actual
FY22
Forecast
FY23
Forecast
EPS (cps) xxx 29.9 57.7 xxx
DPS (cps) xxx 0.0 28.9 xxx
EPS Growth xxx 46.7% 92.9% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 7.4 xxx
Dividend Yield xxx N/A 6.7% xxx
Div Pay Ratio(%) xxx 0.0% 50.1% xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

N/A

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2021 FactSet UK Limited. All rights reserved
Title 201920202021
EPS Basic xxxxxx29.9
DPS All xxxxxx0.0
Sales/Revenue xxxxxx641.3 M
Book Value Per Share xxxxxx40.6
Net Operating Cash Flow xxxxxx153.9 M
Net Profit Margin xxxxxx9.41 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021
Return on Capital Employed xxxxxx80.02 %
Return on Invested Capital xxxxxx22.67 %
Return on Assets xxxxxx14.36 %
Return on Equity xxxxxx80.02 %
Return on Total Capital xxxxxx36.80 %
Free Cash Flow ex dividends xxxxxx102.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Citi

29/09/2021

3

Neutral

$4.50

6.13%

Upgraded first half guidance reflects elevated covid testing, and hence, Citi upgrades its FY22 EPS forecast by 22%. While forecasts for FY23 and FY24 are unchanged (assuming no covid contribution), it's thought these years may provide upside.

Post vaccination, the levels of testing should decrease materially as the focus will switch to  hospitalisation, thinks the analyst. The broker retains its Neutral rating. The target rises to $4.50 from $4.45.

FORECAST
Citi forecasts a full year FY22 dividend of 28.90 cents and EPS of 57.70 cents.
Citi forecasts a full year FY23 dividend of 19.10 cents and EPS of 31.90 cents.

ACL STOCK CHART